Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Substance P-Saporin in terminal cancer patients with intractable pain
NCT02036281Phase 1Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Jan 2014
- Primary completion
- Sep 2016
- Modality
- Recombinant Proteins and Enzymes, Immunotoxins
- Countries
- 1
01
Overview
Phase 1, open-label trial of Substance P-Saporin in pain, sponsored by UT Southwestern Medical Center. Primary endpoint: Response Evaluation Criteria at 8 weeks. Started Jan 2014; status: completed.
02
Drugs
Substance P-Saporin
03
Conditions
pain
Beyond the preview
Go deeper on NCT02036281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02036281.